Last $1.69 USD
Change Today +0.03 / 1.81%
Volume 102.0
As of 8:04 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

oragenics inc (OGEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/14 - $4.65
52 Week Low
05/7/14 - $1.56
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ORAGENICS INC (OGEN)

Related News

No related news articles were found.

oragenics inc (OGEN) Related Businessweek News

No Related Businessweek News Found

oragenics inc (OGEN) Details

Oragenics, Inc. focuses on the discovery, development, and commercialization of various technologies associated with oral health, antibiotics, and other general health benefits. It develops and markets probiotic products comprising ProBiora3, an oral care probiotics that promote oral health for humans and pets under the Evora and ProBiora brands in approximately 13 countries worldwide. The company’s ProBiora3 products include flavored probiotic tablets, such as EvoraPlus and EvoraKids for daily use by adults and children; EvoraPet for companion pets, including cats and dogs; and EvoraPro, a product for the dental office channel. Its product candidates consists of LPT3-04, a naturally occurring compound for weight loss; SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay; and MU1140-S, an antibiotic product candidate in preclinical testing for healthcare-associated infections. Oragenics, Inc. offers its ProBiora3 products through direct-to-consumer channels, professional offices, and private label partnerships. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.

oragenics inc (OGEN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $311.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $200.8K
Vice President of Research & Development
Total Annual Compensation: $177.0K
Compensation as of Fiscal Year 2013.

oragenics inc (OGEN) Key Developments

Oragenics Inc. Approves Amendment to the Amended and Restated Articles of Incorporation

On May 30, 2014, Oragenics Inc. held its Annual meeting of Shareholders, at which Meeting, the company's shareholders authorized the amendment to the Amended and Restated Articles of Incorporation to increase the number of authorized common stock to 100,000,000 shares, upon a determination by Board of Directors that such an increase is in the best interests of company and shareholders.

Oragenics Announces Exclusive Channel Collaboration with Intrexon Corporation

Oragenics Inc. announced that through its Exclusive Channel Collaboration (ECC) with Intrexon Corporation, it has produced and analyzed a large number of new potential analogs generated from its Mutacin 1140 (MU1140) lantibiotic program platform, and advanced several promising compounds for further evaluation. These compounds will serve as the basis for selecting a lead drug candidate for clinical development later in 2014. The triaged analogs were selected from hundreds of variants generated using genetic engineering at Intrexon.

Oragenics Inc. Appoints Al Fosmoe as Senior Vice President Operations/Product Development

Oragenics Inc. announced that Mr. Al Fosmoe has joined Oragenics as Senior Vice President Operations/Product Development. The appointment is directly related to the progress Oragenics has made in the development of a new pipeline of novel antibiotics from its lantibiotic platform, and marks the expansion of the team dedicated to accelerating the progress of the lantibiotic pipeline. Mr. Fosmoe brings to Oragenics more than 25 years of product development, regulatory and commercialization experience in the regulated healthcare products sector, including biologics and drugs. His background spans operational and regulatory oversight for the development of live biotherapeutic products (LBP), biotechnology-derived products, and various oral care products, as well as advancing drug candidates through US and EU clinical trials.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OGEN:US $1.69 USD +0.03

OGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioGaia AB kr181.50 SEK -6.00
BLIS Technologies Ltd $0.02 NZD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation OGEN Industry Range
No financial data is available for OGEN.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORAGENICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at